Research programme: rheumatoid arthritis diagnostics - Roche/Millenium PharmaceuticalsAlternative Names: Rheumatoid arthritis diagnostics research programme - Roche/Millenium Pharmaceuticals
Latest Information Update: 05 Nov 2003
At a glance
- Originator Millennium Pharmaceuticals; Roche
- Developer Millennium Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 05 Nov 2003 No development reported - Preclinical for Rheumatoid arthritis diagnosis in USA (unspecified route)
- 22 Jan 2001 Preclinical development for Rheumatoid arthritis diagnosis in USA (unspecified route)